Shubham Singh is a Business Journalist at Business Today. He focuses on themes related to medicine and healthcare, healthcare technology, and medical innovations, exploring topics such as digital health, telehealth, and software as a service. Shubham's work has been featured in a variety of prominent publications, including .IE, The New Indian Express, and Yahoo Sports.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Shubham Singh's coverage primarily revolves around local events and sports, with a focus on basketball, NBA, and wrestling. He also covers entertainment news to some extent.
Considering his interest in sports and celebrity news, he is likely to respond well to pitches related to local sporting events or profiles of athletes from Andhra Pradesh. For entertainment news, he may be interested in stories about celebrities from the region or unique cultural events.
Given Shubham's geographic focus on India, particularly Andhra Pradesh, pitching stories that align with this geographical scope could increase the chances of successful engagement with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Shubham Singh
Proscia built its business by working with everyone's equipment. Its new owner sells some of that equipment. The $240m deal hands Agilent a software layer for its tissue-diagnostics stack, along with a question about how open that layer can stay.
By: Shubham Singh
International weakness and an Abiomed slump weigh on the segment, while executives promise a better fourth quarter.
By: Shubham Singh
By October 19, 2026 The series of comparisons of the top SEO tools has allowed me to evaluate another set of great tools for beginners and experts.
By: Shubham Singh, Marion Webb, Brian Bossetta, George Underwood
In this week's Digital Health Roundup, BD has struck a $19bn US investment deal for relief from future Section 232 tariffs. UltraSight raises $24m for AI echocardiography, Elixir readies a Japan launch, and Reset Health reports GLP-1 adherence data as it courts NICE.
By: Shubham Singh
Agilent's $240m Proscia deal targets a digital pathology market split in two — clinical labs still largely on glass, biopharma already on screens — with companion diagnostics the clearest near-term opportunity for the acquired software.
By: Shubham Singh
Abbott is spinning off its $8.5bn nutrition business in 2027 with roughly 1,700 infant-formula lawsuits still pending — and CEO Robert Ford has yet to say whether that legal exposure stays with Abbott or goes with the new company.
By: Shubham Singh
Roche's diagnostics division grew 4% in the first nine months of 2026, but the more telling number is what happened in China: a 13% year-to-date decline that is narrowing, with Q3 alone coming in at minus 9% as pricing reform pressure eases.
By: Shubham Singh, Phalguni Deswal
China, Japan and Korea issued AI device documents, Australia applied device rules to AI scribes, and Singapore widened reliance but left devices out of its HTA fast lane. India moved against hospital consumable markups and banned reuse of single-use devices.
By: Shubham Singh
By October 28, 2026 Keyword research is critical for any SEO project to begin, exist, and survive.
By: Shubham Singh
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado's final-mile distribution, as the company bets that supply reliability — not just clinical demand — will determine how fast cardiac PET imaging displaces SPECT.
